

07-10-01



Please type a plus sign (+) inside this box →

UTILITY PATENT APPLICATION TRANSMITTAL

(Only for new nonprovisional applications under 37C.F.R. §1.53(b))

Attorney Docket No. PC10782A

First Named Inventor or Application Identifier S. McLean

Title USE OF DELTA OPIOID RECEPTOR LIGANDS AND SEROTONIN REUPTAKE INHIBITORS IN THE TREATMENT OF CHEMICAL DEPENDENCIES

Express Mail Label No. EL446402275US

**APPLICATION ELEMENTS**

See MPEP chapter 600 concerning utility patent application contents.

- "Fee Transmittal Form (e.g., PTO/SB/17)
(Submit an original, and a duplicate for fee processing)
- Specification [Total Pages 19]
(preferred arrangement set forth below)
 - Descriptive title of the Invention
 - Cross References to Related Applications
 - Statement Regarding Fed sponsored R&D
 - Reference in Microfiche Appendix
 - Background of the Invention
 - Brief Summary of the Invention
 - Brief Description of the Drawings (*if filed*)
 - Detailed Description
 - Claim(s)
 - Abstract of the Disclosure
- Drawing(s) (35 U.S.C. 11.3) [Total sheets]
- Oath or Declaration [Total pages 3]
 - a. Newly executed (original or copy)
 - b. Copy from a prior application (37 CFR §1.63(d))
(for continuation/divisional with Box 17 completed)
[Note Box 5 below]
 - i. DELETION OF INVENTOR(S)
Signed statement attached deleting inventor(s) named in the prior application, see 37 C.F.R. §§ 1.63(d)(2) and 1.33.
- Incorporation By Reference (*useable if Box 4b is checked*)
The entire disclosure of the prior application, from which a copy of the oath or declaration is supplied under Box 4b, is considered to be part of the disclosure of the accompanying application and is hereby incorporated by reference therein.

ADDRESS TO:
Assistant Commissioner for Patents
Box Patent Application
Washington, DC 20231**ACCOMPANYING APPLICATION PARTS**

- Assignment Papers (cover sheet & document(s))
- 37 C.F.R. §3 73(b) Statement Power of Attorney
(when there is an assignee)
- English Translation Document (*if applicable*)
- Information Disclosure Statement (IDS)/PTO-1449 Copies of IDS Citations
- Preliminary Amendment
- Return Receipt Postcard (MPEP 503)
(Should be specifically itemized)
- *Small Entity Statement filed in prior application, Statement(s) (*PTO/SB/09-12*) Status still proper and desired
- Certified Copy of Priority Document(s)
(if foreign priority is claimed)
- Other: Priority Claim
60/217,548
July 12, 2000

**NOTE FOR ITEMS 1-5-6: IN ORDER TO BE ENTITLED TO PAY SMALL ENTITY FEES, A SMALL ENTITY STATEMENT IS REQUIRED (37 C.F.R. 1.27), EXCEPT IF ONE FILED IN A PRIOR APPLICATION IS RELIED UPON (37 C.F.R. § 1.28).*

17. If a CONTINUING APPLICATION, check appropriate box, and supply the requisite information below and in a preliminary amendment.

 Continuation Divisional Continuation-in-part (CIP) of prior application No: /

Prior application information: Examiner _____ Group/Art Unit: _____

18. CORRESPONDENCE ADDRESS

Customer Number or Bar Code Label *(Insert Customer No. or Attach bar code label here)* or Correspondence address below

Name	Paul H. Ginsburg		
Address	Pfizer Inc		
Address	235 East 42nd Street, 20th Floor		
City	New York	State	New York
Country	United States Of America	Telephone	(212)573-2369
NAME (Print/type)	Seth H. Jacobs	Registration No. (Attorney/Agent)	32,140
Signature	<i>Seth H. Jacobs</i>		

FEE TRANSMITTAL

Patent fees are subject to annual revision on October 1.
These are the fees effective October 1, 1997.

Small Entity payments must be supported by a small entity statement,
otherwise large entity fees must be paid. See Forms PTO/SB/09-12.

See 37 C.F.R. §§ 1.27 and 1.28.

Total Amount of Payment (\$) 710.00

METHOD OF PAYMENT (check one)

The commissioner is hereby authorized to charge indicated fees and credit any over payments to:

Deposit Account Number 16-1445

Deposit Account Name Pfizer Inc

Charge Any Additional Fee Required Under 37 C.F.R. §§ 1.16 and 1.17 Charge the Issue Fee Set in 37 C.F.R. § 1.18 at the Mailing of the Notice of Allowance

Payment Enclosed:

Check Money Order Other

FEES CALCULATION**I. BASIC FILING FEE**

Large Entity Fee Code	Fee (\$)	Small Entity Fee Code	Fee (\$)	Fee Description	Fee Paid
101	710	201	355	Utility filing fee	710.00
106	320	206	160	Design filing fee	
107	490	207	245	Plant filing fee	
108	710	208	355	Reissue filing fee	
114	150	214	75	Provisional filing fee	

SUBTOTAL (1) (\$) 710.00

II. EXTRA CLAIM FEES

Total Claims	-20**=	Extra Claims	Fee from below	Fee Paid
10	-20**=	0	X 10 =	0
Independent Claims	- 3**=		X =	
Multiple Dependent			=	0

* or number previously paid; if greater, For Reissues, see below


Large Entity Fee Code (\$)	Fee (\$)	Small Entity Fee Code (\$)	Fee (\$)	Fee Description
103	18	203	9	Claims in excess of 20
102	80		40	Independent claims in excess of 3
104	270	204	135	Multiple dependent claim, if not paid
109	80	209	40	**Reissue independent claims over original patent
110	18	210	9	**Reissue claims in excess of 20 and over original patent

SUBTOTAL (2) (\$) 0

Complete if Known									
Application Number		Unassigned							
Filing Date		Concurrent herewith							
First Named Inventor		S. McLean							
Examiner Name		Unassigned							
Group/Art Unit		Unassigned							
Attorney Docket No.		PC10782A							
FEES CALCULATION (continued)									
3. ADDITIONAL FEES									
Large Entity		Small Entity							
Fee Code	Fee (\$)	Fee Code	Fee (\$)	Fee Description					
105	130	205	65	Surcharge - late fee or oath					
127	50	227	25	Surcharge-late provisional filing fee or cover sheet					
139	130	139	130	Non-English specification					
147	2,520	147	2,520	For filing a request for reexamination					
112	920*	112	920*	Requesting publication of SIR prior to Examiner action					
113	1,840*	113	1,840*	Requesting publication of SIR after Examiner action					
115	110	215	55	Extension for reply within first month					
116	390	216	195	Extension for reply within second month					
117	890	217	445	Extension for reply within third month					
118	1,390	218	695	Extension for reply within fourth month					
128	1,890	228	945	Extension for reply within fifth month					
119	310	219	155	Notice of Appeal					
120	310	220	155	Filing a brief in support of an appeal					
121	270	221	135	Request for oral hearing					
138	1,510	138	1,510	Petition to institute a public use proceeding					
140	110	240	55	Petition to revive - unavoidable					
141	1,240	241	620	Petition to revive - unintentional					
142	1,240	242	620	Utility issue fee (or reissue)					
143	440	243	220	Design issue fee					
144	600	244	300	Plant issue fee					
122	130	122	130	Petitions to the Commissioner					
123	50	123	50	Petitions related to provisional applications					
126	240	126	240	Submission of Information Disclosure Statement					
581	40	581	40	Recording each patent assignment per property (times number of properties)					
146	710	246	355	Filing a submission after final rejection (37 CFR 1.129(a))					
149	710	249	355	For each additional invention to be examined (37 CFR 1.129(b))					
Other Fee (specify)									
Other Fee (specify)									
*Reduced by Basic Filing Fee Paid				SUBTOTAL (3) (\$)					

SUBMITTED BY

Type or Printed Name Seth H. Jacobs

Signature 

Date 9/9/01

Complete (if Applicable)

Reg Number 32,140

Deposit Account User ID

CERTIFICATE OF MAILING EXPRESS MAIL

PFIZER DOCKET NO: PC10782A/SHJ

APPLICATION NUMBER: NOT YET ASSIGNED

TITLE: USE OF DELTA OPIOID RECEPTOR LIGANDS AND SEROTONIN REUPTAKE INHIBITORS IN THE TREATMENT OF CHEMICAL DEPENDENCIES

APPLICANT: S. McLean et al

"Express Mail" mailing label number EL446402275US

Date of Deposit July 9, 2001

I hereby certify that this paper or fee is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 CFR 1.10 on the date indicated above and is addressed to Commissioner for Patents, Box Patent Application, Washington, D.C. 20231.



Michelle D. Dungee

(Signature of person mailing paper or fee)

Pfizer, Inc
Patent Department, 20th Floor
235 East 42nd Street
New York, NY 10017-5755
(212) 733-3189

069001262 - 070500